CBD Education and News
New Regulations on CBD
January 15th, 2020: A bipartisan group of lawmakers introduced a bill that would order the FDA to allow the marketing of CBD as a dietary supplement and food additive, rather than a drug (Aplert, 2019).
What does this mean for the CBD market? This new bill would remove a lot of hurdles that CBD specialists and companies currently face. Back when the 2019 Farm Bill legalized CBD, the CBD market rolled up more than $15 billion in annual sales.
The newly filed bill (H.R. 5587) by House Agriculture Committee Chairman Collin Peterson would classify CBD as a dietary supplement, the same classification as vitamins that requires the FDA to allow on the market without testing required of pharmaceuticals. Legislation to eliminate the hemp holdup would and does have many friendly backers from both sides of the isles.
(Source: Bill Alpert, Barons, Jan. 15 2020)
What is CBD?
What is CBD? Most people are familiar, in some fashion, with THC. THC is the psychoactive ingredient found in the marijuana plant. It’s the thing that gets people high. Did you know there is another ingredient within the plant that also has remarkable health benefits too? That ingredient is CBD, or Cannabidiol, and is rapidly becoming the focus of interest in both medical research and consumer demand.
Where Does CBD Come From? The cannabis plant (typically known as marijuana) is one source of CBD. But cannabis also contains high levels of THC, and under Federal law is an illegal drug. Here’s the good news. The cannabis plant has a cousin – its name is “HEMP”. Unlike cannabis, hemp contains little to no THC, and scientists have discovered how to extract therapeutic and medicinal CBD oil from hemp. The best part is that products produced from industrial hemp are not classified as a drug and are legal to sell in all 50 states. Health Benefits of CBD The health benefits of Cannabidiol (CBD) are well established. Even CNN’s highly respected Chief Medical Correspondent, Dr. Sanjay Gupta, raves about the health benefits of CBD.
The science is clear. We all have an endocannabinoid system (ECS). The ECS is a group of endogenous cannabinoid receptors located in the brain and throughout the central and peripheral nervous systems. CBD specifically interacts with CB1 and CB2 receptors that send signals to wake up and strengthen the immune system naturally. This is because our ECS is intricately intricately linked to our nervous system and immune system, as well as our brain and digestive system. Quality CBD is an extremely effective natural alternative treatment for many ailments and illnesses of various types.
Health Benefits of CBD
The health benefits of Cannabidiol (CBD) are well established. Even CNN’s highly respected Chief Medical Correspondent, Dr. Sanjay Gupta, raves about the health benefits of CBD. The science is clear. We all have an endocannabinoid system (ECS). The ECS is a group of endogenous cannabinoid receptors located in the brain and throughout the central and peripheral nervous systems. CBD specifically interacts with CB1 and CB2 receptors that send signals to wake up and strengthen the immune system naturally. This is because our ECS is intricately linked to our nervous system and immune system, as well as our brain and digestive system. Quality CBD is an extremely effective natural alternative treatment for many ailments and illnesses of various types.
CBD belongs to a class of molecules called cannabinoids, technically phyto-cannabinoids and
are known as neuromodulators or nerve calming. CBD (unlike THC) is not psychoactive.
This attribute has proven to be a God send for people who want the medicinal benefits of
cannabinoids, but don’t want to feel the side effects of THC. Plus CBD has additional health
benefits that THC does not have such as:
• Assist with Pain Relief
• Supports Calmness and Reduced Stress
• Overall Wellness
• Reduces Anxiety
• Natural Sleep Aid
• Healthier Lifestyle
Super Charged Growth in CBD Oils
The marijuana legalization movement in the U.S. has spurred huge investment in an industry that simply didn’t exist just a few years ago.
The great shift in public perception has not only allowed huge swaths of the population to gain access to a product that was once only available on the black market – it has also allowed entrepreneurship to flourish in a new and exciting industry, giving rise to a plethora of U.S.-based “canna businesses.”
Cannabis is now viewed as The Next Great American Industry and according to market research provider, Arcview Market Research, it’s only just beginning. In a “State of Legal Marijuana Markets” report, Arcview found:
— North American marijuana sales grew by an astounding 30% in 2016 to reach $6.7 billion in sales
— North American projected sales to top $20.2 billion by 2021 as markets expand in Canada and USA
According to Arcview’s editor-in-chief Tom Adams, those are hyper-growth projections that draw similarities to cable television (19%) in the 1990’s and the broadband internet (29%) in the 2000’s. And a huge part of that will be fueled by the rapidly accelerating CBD market as well.
According to The CBD Report, published by The Hemp Business Journal, “Hemp CBD market rose from a market that was barely noticeable a few years ago to $90 million in consumer sales for hemp-based CBD products in 2015 alone.”
Projections to date for 2016 indicate that the total CBD market is poised to grow 27% to reach $115 million across channels. In addition to hemp- based CBD products, HBJ estimates another $112 million in cannabis products were sold through dispensaries in 2015, for a total CBD market of $202 million.
As sales of CBD products continue to increase, HBJ forecasts the entire U.S. CBD market will increase to $2.1 billion by 2020 and that $450 million of those sales will be from from hemp based sources, and the rest from marijuana sources.”Amazingly, these projections are only focused on the U.S. CBD market. When you factor in the CAGR of the cannabis market in places like Canada, Australia, the U.K., and Europe, these numbers could be staggering.
In fact, Matt Karnes of Greenwave Advisors is even more optimistic about its growth growth prospects, saying, “In terms of the CBD market size, I estimate an almost $3 billion market by 2021.” A growing number of investors believe those lofty projections may even be too conservative.
Big Pharma Concerned about CBD
GW Pharmaceuticals is a UK company that’s developing Epidiolex – a novel CBD treatment for severe, orphan, early-onset, treatment-resistant epilepsy syndromes including Dravet syndrome, Lennox-Gastaut syndrome (LGS), Tuberous Sclerosis Complex (TSC) and Infantile Spasms (IS).
Now keep in mind, the global epilepsy drugs market alone was valued at $4.1 billion in 2015. However, these treatments have proven to be highly ineffective in controlling epilepsy syndromes. What’s worse, existing anti-epileptic drugs often have brutal side effects that can cause permanent damage to a patient’s body and mind. Because Epidiolex was developed to compete against these ineffective and harmful drugs, it has the potential to seize control of the antiepileptic drug market completely – which could quickly translate into blockbuster sales figures.
Not surprisingly, this potential upside has boosted the stock value of GW Pharmaceuticals (NASDAQ:GWPH) significantly over the last few years. From a share price of just $8.46 on June 12, 2013, the company’s stock has exploded higher – reaching a price of $136.95 per share on March 3, 2017.
That’s a gain of 1,518% in less than 4 years. Their market capitalization today (which can be viewed as the current market value of the company) is almost $3 billion.
This goes to show that even though this company loses tens of millions of dollars every year and has never turned a profit, investors are betting heavily that GW Pharmaceutical’s CBD drug will deliver blockbuster profits in the future. That upside is being priced into their stock today.
And that’s just for epilepsy.
CBD has shown immense promise for the treatment of many other conditions as well. We won’t go through the entire list, but here are just a few conditions in which researchers are investigating CBD’s potential for future drug treatment:
- Alzheimer’s Disease
- Heart Disease
- Metabolic Syndrome
- Multiple Sclerosis (MS)
If GW Pharmaceuticals can succeed in displacing traditional medications for epilepsy, then watch out. That could potentially clear the way for the development of CBD to combat numerous other conditions – potentially making today’s ineffective and potentially harmful medications obsolete.
The CBD and Cannabis Market is Exploding
Unless you’ve been living under a rock in the last few years, you’ve probably heard about cannabidiol or CBD products. This non-addictive, non-psychoactive chemical compound is found in the cannabis plant has been hailed as the powerful plant-based medication that is extremely promising for a wide variety of conditions and ailments. CBD packs preventive properties that may help the following symptoms:
Helps prevent pediatric seizures
A natural anti-inflammatory for skin and soft tissue
This antioxidant helps fight tumor and cancer cells
Fights germs and bacteria
Can enhance brain health
Eases chronic pain
(source: Jill Anderson, In CBD (Cannabidiol). August 16, 2017)
CBD And Pregnancy
With CBD having a large number of benefits such has helping with nausea, muscle pain, cramps, and sleep problems, a question beckons; is CBD safe to use while pregnant?
The FDA addressed this question with an in depth study. Obviously the use of marijuana with THC can cause issues during child development, but when looking at CBD there is no comprehensive research studying the effects of CBD during child development (FDA, 2019). The FDA is continuing to collect data and study the possible effects of CBDs during pregnancy and while breastfeeding, harmful or not.
The slight concern: High Dose CBD tests on pregnant animals have caused problems with the reproductive system of developing male fetuses, but there are still in depth studies to further evaluate CBD.
(Source: Food and Drug Administration, information current as of October 16, 2019)